Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Andrew Wang Added: 6 days ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive… View more
Author(s): Javed Butler Added: 2 months ago
ESC Congress 2025 - Vericiguat significantly reduced risks of CV mortality and HF hospitalisations, as well as all-cause mortality across both the VICTOR and VICTORIA Trial.Dr JavedButler (Baylor Scott & White Health, Dallas, US) joins us to discuss findings from a pooled analysis of the recent VICTOR and VICTORIA trials, with data from 11155 participants with heart failure with reduced ejection… View more
Author(s): Ahmad Masri Added: 1 month ago
HFSA 25 - Aficamten found to significantly improve NYHA and KCCQ-CSS scores in new 96-week data from FOREST-HCM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss findings from the FOREST-HCM trial, examining the sustained safety and efficacy of aficamten in patients with symptomatic nonobstructive hypertrophic cardiomyopathy.This phase 2 open-label study followed 34… View more
Author(s): Rajiv Agarwal Added: 1 month ago
EASD 2025 - Simultaneous finerenone and empagliflozin was a safe therapy option in patients with diabetes and chronic kidney disease (CKD).Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) joins us to discuss safety and efficacy findings from a double-blind, randomised, prespecified subanalysis of CONFIDENCE (NCT05254002), investigating simultaneous finerenone and… View more
Author(s): Ankeet Bhatt Added: 5 months ago
ESC HF 25 - Secondary analysis of the FINEARTS-HF study shows finerenone treatment favourably influenced the risk of early heart failure readmission.Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, San Francisco, US) discusses findings from the prespecified secondary analysis of the FINEARTS-HF trial (NCT04435626; Bayer). The placebo-controlled primary analysis investigated the… View more
Author(s): Rajesh Kharbanda Added: 5 months ago
EuroPCR 25 - A meta-analysis of the individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI studies show TAVI with cerebral embolic protection (CEP) may reduce the rate of disabling stroke compared to TAVI without CEP.We are joined by Prof Rajesh Kharbanda (Oxford Radcliffe Hospitals NHS Trust, Oxford, UK) to discuss outcomes from a meta-analysis investigating TAVI with or without… View more
Author(s): Raj Makkar Added: 5 months ago
EuroPCR 25 - Post-hoc anlysis outcomes from under-expansion of the ACURATE neo2 valve in severe aortic stenosis (AS) patients show under-expansion was associated with higher rates of death, stroke or rehospitalisation.We are joined by Dr Raj Makkar (Cedars-Sinai Heart Institute, Los Angeles, US) to discuss findings from the post-hoc analysis of the ACURATE IDE study (NCT03735667; Boston… View more